Overview

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients

Status:
Unknown status

Trial end date:
2005-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare an angiotensin II receptor antagonist (candesartan cilexetil- Blopress®) and a calcium channel blocker (amlodipine besilate- Norvasc®/Amlodin®) in terms of the incidence of cardiovascular events among high-risk hypertensive patients.

Phase:

Phase 3

Details

Lead Sponsor:

The Japanese Society of Hypertension

Treatments:

Antihypertensive Agents
Candesartan
Candesartan cilexetil